Bristol Myers Squibb Co  (BMY)
Other Ticker:  

Bristol Myers Squibb Co's



BMY Sales vs. its Competitors Q2 2021

Comparing the results to its competitors, Bristol Myers Squibb Co reported Total Revenue increase in the 2 quarter 2021 by 15.54 % year on year.
The revenue growth was below Bristol Myers Squibb Co's competitors average revenue growth of 24.07 %, recorded in the same quarter.

List of BMY Competitors

With net margin of 9.07 % company reported lower profitability than its competitors.

More on BMY Margin Comparisons

Revenue Growth Comparisons

Net Income Comparison

Bristol Myers Squibb Co achieved net profit of $1,061 millions compare to net loss of $-80 millions recorded in same quarter a year ago.

<<  More on BMY Income Comparisons

Bristol Myers Squibb Co's Comment on Competitors and Industry Peers

The markets in which we compete are generally broad based and highly competitive. We compete with other worldwide research-based drug companies, many smaller research companies with more limited therapeutic focus and generic drug manufacturers. Important competitive factors include product efficacy, safety and ease of use, price and demonstrated cost-effectiveness, marketing effectiveness, product labeling, customer service and research and development of new products and processes. Sales of our products can be impacted by new studies that indicate a competitor’s product is safer or more effective for treating a disease or particular form of disease than one of our products. Our revenues also can be impacted by additional labeling requirements relating to safety or convenience that may be imposed on products by the FDA or by similar regulatory agencies in different countries. If competitors introduce new products and processes with therapeutic or cost advantages, our products can be subject to progressive price reductions or decreased volume of sales, or both.

Generic Competition

One of the biggest competitive challenges that we face is from generic pharmaceutical manufacturers. In the U.S. and the EU, the regulatory approval process exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy of the innovator product. As a result, generic pharmaceutical manufacturers typically invest far less in research and development than research-based pharmaceutical companies and therefore can price their products significantly lower than branded products. Accordingly, when a branded product loses its market exclusivity, it normally faces intense price competition from generic forms of the product. Upon the expiration or loss of market exclusivity on a product, we can lose the major portion of revenues of that product in a very short period of time.

The rate of revenues decline of a product after the expiration of exclusivity varies by country. In general, the decline in the U.S. market is more rapid than in most other developed countries, though we have observed rapid declines in a number of EU countries as well. Also, the declines in developed countries tend to be more rapid than in developing countries. The rate of revenues decline after the expiration of exclusivity has also historically been influenced by product characteristics. For example, drugs that are used in a large patient population (e.g., those prescribed by key primary care physicians) tend to experience more rapid declines than drugs in specialized areas of medicine (e.g., oncology). Drugs that are more complex to manufacture (e.g., sterile injectable products) usually experience a slower decline than those that are simpler to manufacture.


Overall company Market Share Q2 2021

Despite strong revenue increase of 15.54 % in Overall company, Bristol Myers Squibb Co lost market share, to approximate 10.55 %.

<<  More on BMY Market Share.

*Market share calculated with total revenue.

BMY's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

Bristol Myers Squibb Co 44,384 129,271 -5,059 25,000
Actavis Plc 10,573 4,007 -751 19,200
Cephalon, Inc. 0 0 0 0
Johnson and Johnson 89,190 437,368 17,767 126,500
Merck and Co Inc 48,547 205,460 5,585 70,000
Mylan N v 16,861 8,208 266 25,000
Pfizer Inc 57,374 245,233 13,282 78,300
Watson Pharmaceuticals Inc 0 0 0 0
Abbott Laboratories 40,233 227,370 6,376 77,000
Eli Lilly And Company 26,726 221,910 6,071 39,135
Wyeth 0 0 0 0
Abbvie Inc 53,729 193,975 6,675 26,000
Bard C R Inc 5,308 28,675 690 13,900
Gilead Sciences Inc 26,638 84,722 5,136 7,000
Amgen Inc 32,341 120,522 5,746 17,900
Celgene Corp 16,982 78,961 1,834 6,012
Balchem Corporation 744 5,052 90 1,060
Dupont De Nemours Inc 18,459 38,374 6,043 63,000
Fmc Corporation 4,674 12,099 546 5,900
Mead Johnson Nutrition Co 7,341 18,307 653 7,200
Synutra International, Inc. 345 0 24 2,600
Zivo Bioscience Inc 0 25 -9 2
Alexion Pharmaceuticals Inc 6,262 40,625 535 2,273
Biogen Inc 11,101 39,349 2,106 7,550
Covidien Plc 10,880 0 1,605 39,500
SUBTOTAL 528,691 2,139,512 75,210 660,032


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

IBEX's Profile

Stock Price

IBEX's Financials

Business Description


Charts & Quotes

IBEX's News


IBEX's Competitors

Customers & Markets

Economic Indicators

IBEX's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071